Solid Tumor Testing Market in Australia

Solid Tumor Testing in Australia Trends and Forecast

The future of the solid tumor testing market in Australia looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1641.7 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The solid tumor testing market in Australia is also forecasted to witness strong growth over the forecast period. The major drivers for this market are an increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.

• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.

Emerging Trends in the Solid Tumor Testing Market in Australia

The Australian market for solid tumor testing is shifting as demand increases for accurate and tailored cancer diagnostics. With cancer being a leading cause of death, genomic profiling, liquid biopsy, and AI imaging are transforming early detection, monitoring, and treatment. Additionally, drug response prediction is improving with RNA testing and tumor organoid models. These advancements are expected to enhance cancer diagnosis and treatment in Australia, significantly improving patient outcomes and transforming oncology into a more personalized approach.

• Increased Use of Genomic Profiling: Comprehensive genomic profiling (CGP) is now standard practice in Australia, helping practitioners detect specific tumor mutations that can be treated with targeted therapies. CGP analyzes hundreds of genes in cancer patients, making treatment more precise. As access to CGP improves, it is expected to become the norm in cancer diagnosis, ensuring that patients receive treatment based on their genetic makeup rather than traditional chemotherapy.
• Improvement in Liquid Biopsy: Liquid biopsy is gaining popularity as a less invasive alternative to traditional tumor biopsies. This method detects circulating tumor DNA (ctDNA) in the blood, allowing for early diagnosis, therapy monitoring, and resistance testing. Australian research institutions are developing highly sensitive liquid biopsy tests to improve cancer detection rates and enable real-time tumor monitoring. This technology is expected to reduce the need for invasive procedures while allowing for timely and personalized treatment modifications.
• Improved Imaging with AI: Australia is integrating AI technologies into its healthcare system to improve diagnostic accuracy. Advanced medical software uses algorithms to analyze images, identify cancerous growths, minimize human errors, and accelerate diagnosis. AI-powered PET/CT scanners provide high-quality imaging with lower radiation doses, improving patient safety. These innovations simplify the work of physicians and enable oncologists to deliver more efficient and precise healthcare services.
• The New Wave of Fusion Testing with RNA: In Australia, RNA-based fusion testing is proving essential in diagnostics, particularly for identifying gene fusions that DNA tests fail to detect. This is especially beneficial for rare and aggressive cancers, expanding treatment options for patients who may not benefit from traditional genetic testing. As more clinical laboratories adopt RNA fusion panels, oncologists can prescribe targeted, mutation-specific therapies, ultimately improving patient survival rates.
• Development of Tumor Organoids: Australian scientists are pioneering the development of 3D cancer models using tumor organoids—cultures derived from patient tumors that replicate real tumor behavior. These organoids allow oncologists to test multiple treatment options before applying them to patients, ensuring more accurate drug response predictions. This approach reduces trial-and-error treatments, leading to more effective therapies and improved patient care.

Australia’s solid tumor testing market is evolving through innovations in genetic profiling, liquid biopsy, AI-assisted imaging, and RNA-based testing. These advancements are providing Australians with more precise and timely cancer treatments. As these technologies continue to develop, they offer novel approaches to cancer diagnosis and treatment, ensuring better patient outcomes.

Recent Developments in the Solid Tumor Testing Market in Australia

The solid tumor testing market in Australia is undergoing significant changes driven by innovative research, public policy, and emerging technologies. Advances in diagnostic tools, expanded access to genetic testing, and AI-driven accuracy are improving cancer detection. The growth of liquid biopsy and personalized treatment methods is enhancing patient care. These developments are not only improving cancer diagnosis but also leading to more precise treatment approaches, ensuring that patients receive optimal care.

• Government Investment in Genomic Research: The Australian government has increased funding for genomic research and is supporting initiatives that integrate genomic profiling into routine cancer care. Programs such as the Australian Genomics Health Alliance are working to expand access to next-generation sequencing (NGS), ensuring that more patients can receive targeted therapies. This funding is accelerating the adoption of precision medicine and broadening the availability of genetic testing across public and private healthcare systems.
• Expansion of Liquid Biopsy Clinical Trials: Australian research centers are conducting large-scale clinical trials to establish liquid biopsy as a standard diagnostic tool. These studies are evaluating its effectiveness in early cancer detection, treatment response assessment, and minimal residual disease detection. With promising trial results, liquid biopsy is moving toward routine clinical use as it is safer and more convenient than traditional tissue biopsies. This development is expected to transform cancer diagnostics by making patient monitoring more efficient and accessible.
• Integration of AI in Pathology: The accuracy and speed of cancer diagnosis in Australian laboratories are improving with the integration of AI tools. AI algorithms assist pathologists in analyzing tissue samples, identifying abnormalities that might be overlooked, and reducing diagnostic errors. These platforms are streamlining workflows and significantly accelerating result processing. As AI tools continue to advance, the precision and efficiency of cancer diagnostics in Australia are expected to reach new heights.
• Breakthroughs in Tumor Microenvironment Research: Australian scientists are making significant progress in understanding the tumor microenvironment (TME) and its interaction with the immune system. Research on TME biomarkers is leading to the development of new immunotherapies for specific cancer subtypes. Oncologists are now better equipped to enhance treatment outcomes while minimizing side effects. These advancements are bringing cancer treatment closer to a more targeted and effective approach.
• Establishment of Genomic Cancer Centers: Australia has recognized the need for national genomic cancer centers to improve standards in cancer care. The creation of a national cancer genomics program aims to provide patients with integrated, high-quality care. Advancements in AI diagnostics, liquid biopsy, and tumor microenvironment research will contribute to a more efficient and personalized cancer care system in Australia.

Australia’s solid tumor testing market is advancing through government investments, clinical trials, AI-driven pathology, tumor microenvironment research, and genomic cancer centers. These developments are revolutionizing cancer diagnostics and treatment, ensuring that patients receive faster, more precise, and highly personalized care. As research and technology continue to progress, the future of cancer testing in Australia looks increasingly promising.

Strategic Growth Opportunities for Solid Tumor Testing Market in Australia

The market for testing solid tumors in Australia is rapidly evolving due to technological advancements, higher rates of cancer cases, and the trend toward precision medicine. The implementation of molecular diagnostic and liquid biopsy methods is improving early diagnosis, treatment precision, and patient outcomes. Cancer continues to be one of the leading causes of death, so healthcare players will prioritize important use cases with substantial growth prospects. This report identifies five critical opportunities in solid tumor testing in Australia.

• Diagnosing Breast Cancer: New technologies in breast cancer genomic testing will change how patients are diagnosed and how their treatment is chosen. Molecular profiling techniques such as Next-Generation Sequencing (NGS) and liquid biopsies make it possible to detect mutations in genes like BRCA1/2 at an early stage. These technologies promote a shift toward more personalized treatment approaches by reducing dependency on chemotherapy while improving survival outcomes. Additionally, awareness and screening uptake are further propelled by government-funded campaigns. In precision oncology, the demand for advanced breast cancer diagnostics will increase, creating significant market growth opportunities.
• Lung Cancer Screening: Through the application of low-dose computed tomography (LDCT) with molecular testing, the prospect of lung cancer detection is improving. The liquid biopsy method for detecting mutations, such as EGFR and ALK, enables targeted and more effective treatment. Australia’s efforts to reduce deaths resulting from lung cancer, especially among high-risk populations, are creating a need for more accurate and non-invasive diagnostic methods. Multi-omics and AI-powered image analysis are other segments of accelerated research that strengthen this market. For these reasons, lung cancer screening stands out as one of the crucial areas of development.
• Colorectal Cancer Testing: The adoption of non-invasive testing, such as fecal immunochemical tests (FIT) and stool DNA tests, is increasing screening for colorectal cancer. The latest developments in molecular diagnostics, including microsatellite instability (MSI) and RAS mutation tests, are also improving targeted treatment. There has been a surge in participation in government-sponsored screening programs and patient education. These factors should decrease the incidence rates of the disease. Additionally, the need for precise and non-invasive diagnostics gives Australian companies investing in colorectal cancer testing an advantage in the market.
• Detecting Melanoma: Australia has the highest incidence rate of melanoma in the world, creating a significant need for advanced melanoma diagnostic solutions. The incorporation of new technologies such as AI-powered dermatoscopy and blood-based biomarkers is improving early melanoma detection. Recent advancements in melanoma blood tests that detect microRNA signatures offer a non-invasive alternative to traditional biopsy methods. Implementing these innovations enhances diagnostic accuracy and accelerates treatment initiation, positioning melanoma testing as one of the fastest-growing segments within the solid tumor testing industry.
• Assessing Prostate Cancer: The prostate cancer diagnosis process is changing with the introduction of multi-parametric MRI, genomic biomarkers, and novel PSA-based risk stratification approaches. These innovations help clinicians distinguish between aggressive and indolent tumors, minimizing unnecessary biopsies and overtreatment. These processes are further streamlined with liquid biopsy for prostate cancer in primary diagnosis and management. An aging population and growing awareness of personalized medicine will make prostate cancer imaging and diagnosis in Australia a substantial opportunity, contributing significantly to market growth.

The Australian solid tumor testing market is expanding across major applications due to technological advancements, increased cancer awareness, and a shift toward personalized medicine. Newer techniques in diagnosing breast, lung, colorectal, melanoma, and prostate cancers are improving detection and treatment, leading to better patient prognoses. With the growth of non-invasive testing, the use of biomarkers in cancer diagnosis and treatment will increase, driving market expansion. Early adopters of novel diagnostic methods stand to benefit from changing market dynamics.

Solid Tumor Testing Market in Australia Driver and Challenges

The solid tumor testing market in Australia is influenced by multiple key drivers and challenges spanning technology, economics, and regulatory frameworks. The increasing use of precision oncology, government-sponsored screening programs, and enhanced diagnostic systems are creating favorable conditions for market growth. However, challenges such as high test costs, strict regulations, and limited market accessibility remain. Understanding the interplay of these factors is essential for stakeholders. This report discusses five factors driving strong market growth and three challenges that hinder developments in Australia’s solid tumor testing market.

The factors responsible for driving the solid tumor testing market in Australia include:
• Technological Developments in Molecular Diagnostics: Recent advancements in molecular testing technologies, including next-generation sequencing (NGS), liquid biopsy, and AI in pathology, are improving solid tumor diagnosis. These innovations allow for earlier identification, better risk categorization, and personalized treatment planning. Misdiagnosis rates are decreasing, and treatment responses are improving as genomic profiling becomes more common in clinical practice. As technology advances, the expanded use of sophisticated molecular diagnostic tools will drive market growth.
• Government Programs for Cancer Screening: The Australian government actively supports cancer screening through initiatives such as the National Bowel Cancer Screening Program and BreastScreen Australia. These programs aim to enhance early cancer diagnosis, stimulating demand for effective, intelligent, and cost-efficient diagnostic tests. Increased public sector investment in promoting cancer screening is positively impacting the market. Nationwide screening programs will lead to earlier diagnoses, benefiting both patients and the industry.
• Rising Incidence of Cancer: With an increasing number of cancer cases, there is greater demand for early and accurate cancer diagnostics. An aging population, lifestyle changes, and environmental factors contribute to the rising cancer burden in Australia. This growing burden fuels demand for effective solid tumor testing, driving innovation and investment in the field. Companies providing cancer detection solutions stand to gain from this expanding market need.
• Expansion of Personalized Medicine: The shift toward personalized cancer care is significantly impacting demand for tumor testing services. Precision medicine strategies require genomic and biomarker testing to develop patient-specific therapies. Targeted therapies and immunotherapy are gaining traction due to the increasing demand for companion diagnostics, particularly in cancer treatment. As the pharmaceutical sector continues to introduce new treatments focused on biomarkers, the demand for tumor testing will rise substantially.
• Increasing Investment in Research and Development: Australia has a strong research ecosystem in cancer diagnostics and precision oncology. The government is providing grants, academic institutions are collaborating, and the private sector is investing in tumor testing innovations. Advances in blood-based biomarkers, AI-assisted diagnostics, and digital pathology are improving testing accuracy and accessibility. These investments are driving the commercialization of cutting-edge diagnostic tools, offering significant potential for market expansion.

Challenges in the solid tumor testing market in Australia are:
• High Costs of Advanced Diagnostic Tests: Despite technological advancements, access to molecular and advanced testing remains a significant challenge. Next-generation sequencing (NGS) and liquid biopsy tests are expensive and have limited use in routine clinical practice. While some tests receive government funding, more comprehensive reimbursement policies are necessary. Public healthcare systems need to adopt cost-effective alternatives to ensure broader accessibility.
• Regulatory and Reimbursement Challenges: Australia’s regulatory environment presents obstacles for diagnostic companies. New testing technologies undergo lengthy approval processes, delaying market entry. Additionally, limited reimbursement for advanced diagnostics hinders clinical adoption. Streamlining regulatory approvals and expanding coverage for innovative tumor tests are necessary for market growth.
• Limited Access to Advanced Testing in Remote Areas: Access to high-tech solid tumor testing remains difficult in certain regions of Australia, particularly in rural and remote areas. The concentration of diagnostic services in urban centers limits early cancer detection and treatment options for underserved populations. Expanding telemedicine, mobile diagnostics, and decentralized testing solutions can help bridge this gap, ensuring equitable access to quality cancer diagnostics nationwide.

The solid tumor testing market in Australia is evolving due to technological advancements, government initiatives, and the growing need for precision medicine. However, challenges such as regulatory barriers, high costs, and limited healthcare access persist. If stakeholders invest in innovation and policy improvements, the market will continue to grow. Addressing these challenges will enhance cancer diagnostics, benefiting both patients and the industry in Australia.

List of Solid Tumor Testing Market in Australia Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, solid tumor testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10

Solid Tumor Testing Market in Australia by Segment

The study includes a forecast for the solid tumor testing market in Australia by type, application, and end use.

Solid Tumor Testing Market in Australia by Type [Analysis by Value from 2019 to 2031]:

• Genetic Testing
• Conventional Testing

Solid Tumor Testing Market in Australia by Application [Analysis by Value from 2019 to 2031]:

• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others

Solid Tumor Testing Market in Australia by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions

Features of the Solid Tumor Testing Market in Australia

Market Size Estimates: Solid tumor testing in Australia market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Solid tumor testing in Australia market size by type, application, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, application, and end use for the solid tumor testing in Australia.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing in Australia.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q1. What are the major drivers influencing the growth of the solid tumor testing market in Australia?
Answer: The major drivers for this market are increase in the utilization of supplements and steroids and increase in unhealthy habits, such as smoking and alcohol consumption.
Q2. What are the major segments for solid tumor testing market in Australia?
Answer: The future of the solid tumor testing market in Australia looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets.
Q3. Which solid tumor testing market segment in Australia will be the largest in future?
Answer: Lucintel forecasts that melanoma is expected to witness the highest growth over the forecast period due to growing incidence of skin tumors and related conditions globally.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 10 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market in Australia by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), and end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Solid Tumor Testing Market in Australia, Solid Tumor Testing Market in Australia Size, Solid Tumor Testing Market in Australia Growth, Solid Tumor Testing Market in Australia Analysis, Solid Tumor Testing Market in Australia Report, Solid Tumor Testing Market in Australia Share, Solid Tumor Testing Market in Australia Trends, Solid Tumor Testing Market in Australia Forecast, Solid Tumor Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.